​

Phathom Pharmaceuticals (PHAT) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

PHAT Stock Forecast

Phathom Pharmaceuticals (PHAT) stock forecast, based on 8 Wall Street analysts, predicts a 12-month average price target of $23.33, with a high of $28.00 and a low of $16.00. This represents a 123.47% increase from the last price of $10.44.

$5 $10 $15 $20 $25 $30 High: $28 Avg: $23.33 Low: $16 Last Closed Price: $10.44

PHAT Stock Rating

Phathom Pharmaceuticals stock's rating consensus is Buy, based on 8 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 7 Buy (87.50%), 1 Hold (12.50%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 8 0 1 7 Strong Sell Sell Hold Buy Strong Buy

PHAT Price Target Upside V Benchmarks

TypeNameUpside
StockPhathom Pharmaceuticals123.47%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts116
Avg Price Target$28.00$28.00$23.33
Last Closing Price$10.44$10.44$10.44
Upside/Downside168.20%168.20%123.47%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Mar, 26182--11
Feb, 26182--11
Jan, 26182--11
Dec, 25171--9
Nov, 25261--9
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Feb 26, 2026Annabel SamimyStifel Nicolaus$28.00$13.62105.58%168.20%
Dec 11, 2025Martin AusterRaymond James$28.00$14.5692.31%168.20%
Dec 08, 2025Jenna DavidnerBarclays$16.00$14.907.38%53.26%
Oct 31, 2025Chase KnickerbockerCraig-Hallum$22.00$13.7659.88%110.73%
Oct 31, 2025H.C. Wainwright$26.00$13.3195.34%149.04%
Oct 30, 2025Yatin SunejaGuggenheim$20.00$13.3150.26%91.57%
Mar 07, 2025Guggenheim$18.00$5.06255.73%72.41%
Aug 08, 2024Paul ChoiGoldman Sachs$12.00$11.752.13%14.94%
Jul 19, 2024Matthew CaufieldH.C. Wainwright$28.00$10.95155.71%168.20%
May 02, 2024Annabel SamimyStifel Nicolaus$24.00$9.76145.90%129.89%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jan 14, 2026Cantor FitzgeraldOverweightOverweighthold
Dec 11, 2025Raymond JamesStrong Buyinitialise
Dec 08, 2025BarclaysNeutralinitialise
Oct 31, 2025Craig-HallumBuyBuyhold
Oct 31, 2025H.C. WainwrightBuyBuyhold
Oct 30, 2025GuggenheimBuyBuyhold
Jun 06, 2025CitigroupBuyBuyhold
May 02, 2025H.C. WainwrightBuyBuyhold
Mar 07, 2025Craig-HallumBuyBuyhold
Aug 08, 2024Goldman SachsNeutralNeutralhold

Financial Forecast

EPS Forecast

$-8 $-6 $-4 $-2 $0 $2 $3 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-3.93$-5.29$-3.03---
Avg Forecast$-3.72$-5.41$-4.12$-1.61$0.70$1.82
High Forecast$-3.32$-3.78$-2.88$-0.27$1.68$2.48
Low Forecast$-4.12$-7.38$-5.61$-2.31$-0.28$1.27
Surprise %5.65%-2.22%-26.46%---

Revenue Forecast

$0 $200M $400M $600M $800M $1B Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$682.00K$55.25M$175.11M---
Avg Forecast$394.86K$51.63M$175.07M$383.68M$599.45M$763.24M
High Forecast$437.16K$55.00M$218.32M$391.75M$614.74M$976.80M
Low Forecast$347.85K$46.69M$131.11M$375.62M$584.16M$586.59M
Surprise %72.72%7.02%0.02%---

Net Income Forecast

$-400M $-290M $-180M $-70M $40M $150M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-201.59M$-334.33M----
Avg Forecast$-201.59M$-339.44M$-217.81M$-66.16M$35.90M$93.35M
High Forecast$-170.43M$-193.93M$-147.63M$-13.73M$86.01M$127.30M
Low Forecast$-211.45M$-378.30M$-287.99M$-118.59M$-14.21M$65.26M
Surprise %--1.51%----

PHAT Forecast FAQ

Is Phathom Pharmaceuticals stock a buy?

Phathom Pharmaceuticals stock has a consensus rating of Buy, based on 8 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 7 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Phathom Pharmaceuticals is a favorable investment for most analysts.

What is Phathom Pharmaceuticals's price target?

Phathom Pharmaceuticals's price target, set by 8 Wall Street analysts, averages $23.33 over the next 12 months. The price target range spans from $16 at the low end to $28 at the high end, suggesting a potential 123.47% change from the previous closing price of $10.44.

How does Phathom Pharmaceuticals stock forecast compare to its benchmarks?

Phathom Pharmaceuticals's stock forecast shows a 123.47% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Phathom Pharmaceuticals over the past three months?

  • March 2026: 9.09% Strong Buy, 72.73% Buy, 18.18% Hold, 0% Sell, 0% Strong Sell.
  • February 2026: 9.09% Strong Buy, 72.73% Buy, 18.18% Hold, 0% Sell, 0% Strong Sell.
  • January 2026: 9.09% Strong Buy, 72.73% Buy, 18.18% Hold, 0% Sell, 0% Strong Sell.

What is Phathom Pharmaceuticals’s EPS forecast?

Phathom Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December 2026 is $-1.61, marking a -46.86% decrease from the reported $-3.03 in 2025. Estimates for the following years are $0.7 in 2027, and $1.82 in 2028.

What is Phathom Pharmaceuticals’s revenue forecast?

Phathom Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December 2026 is $383.68M, reflecting a 119.11% increase from the reported $175.11M in 2025. The forecast for 2027 is $599.45M, and $763.24M for 2028.

What is Phathom Pharmaceuticals’s net income forecast?

Phathom Pharmaceuticals's net income forecast for the fiscal year ending in December 2026 stands at $-66.161M, representing a 0% decrease from the reported $0 in 2025. Projections indicate $35.9M in 2027, and $93.35M in 2028.